MetaCap

Codexis Inc. (CDXS)

NASDAQ: CDXSIndustrialsMajor ChemicalsUSD

1.01-0.04 (-3.81%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

CDXS stock chart

Technical analysis

Key statistics

All statistics
Market cap
$110.69M
EPS (TTM)
-$0.18
52-week range
0.90 – 2.98
Day range
0.98 – 1.06
Volume / Avg
2.07M / 918.15K
Beta
—

52-week range

$0.90$2.98

CDXS stock today

Codexis (CDXS) closed at $1.01 on Nov 20, down 3.81% (-$0.04), versus the S&P 500's 3.70% decline. Volume was 2.3x the average at 2.07M shares, a sign of unusually heavy trading. At this level, CDXS sits near the bottom of its 52-week range of $0.90 to $2.98: 66.1% below the high, set on May 11, 2026 and 12.2% above the low.

CDXS is down 38.0% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 34.4%. Codexis has posted a net loss over the last twelve months (EPS of -$0.18), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About Codexis

Company profile

Codexis, Inc. provides technology solutions for therapeutics manufacturing, leveraging its proprietary CodeEvolver technology platform to discover, develop, enhance, and commercialize novel enzymes in the United States, Canada, Latin America, Europe, the Middle East, Africa, Australia, New Zealand, Southeast Asia, and China. The company develops its proprietary ECO Synthesis manufacturing platform to enable the scaled manufacture of RNAi therapeutics through an enzymatic route.

Industry
Major Chemicals
CEO
Dr. Alison Moore Ph.D.
Headquarters
Redwood City, CA
Employees
146
IPO year
2010

Financial highlights

Full financials

In fiscal 2025, Codexis generated $70.4 million in revenue, up 18.6% from fiscal 2024. Codexis reported a net loss of $44.0 million, compared with a loss of $65.3 million a year earlier. Gross margin was 86.7% (up from 72.6%) and operating margin -59.3%.

Codexis annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue$70.39M$59.34M$70.14M$138.59M$104.75M
Growth+18.61%-15.39%-49.39%+32.30%+51.69%
Net income$-43.97M$-65.28M$-76.24M$-33.59M$-21.28M
EPS (diluted)$-0.50$-0.89$-1.12$-0.51$-0.33

Analyst forecast

Forecast

Consensus (8 analysts)

buy

Avg. price target

$6.14+507.92%

  • Strong buy 1
  • Buy 5
  • Hold 2
  • Sell 0
  • Strong sell 0

Target range

Low $2.00High $11.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 12, 2026
EPS actual vs est.
$-0.22 vs $-0.09
Surprise
-144.44%

CDXS news

All CDXS news

Codexis peers

Industrials sector
CDXS peer companies
CompanyPrice% ChgMarket capCompare
ACNTAscent Industries Co.12.42-0.88%$112.05Mvs CDXS
LODEComstock Inc.1.32-2.94%$100.39Mvs CDXS
ARQArq Inc.2.82-3.42%$124.61Mvs CDXS
LTBRLightbridge Corporation3.24-9.13%$125.40Mvs CDXS
FFFutureFuel Corp.2.93-2.33%$128.52Mvs CDXS
FSIFlexible Solutions International Inc.5.86-1.18%$74.86Mvs CDXS
VGASVerde Clean Fuels Inc. Class A0.935-1.58%$62.69Mvs CDXS
AMTXAemetis Inc. (DE)0.8092-14.52%$59.15Mvs CDXS

Indexes, lists and sector

Codexis stock FAQ

What is Codexis's stock price today?

CDXS last traded at $1.01 as of Nov 20, 4:00 PM EST, down 3.81% on the day. Prices are delayed at least 15 minutes.

Who is Codexis's CEO?

Dr. Alison Moore Ph.D. is the chief executive officer of Codexis Inc., which has about 146 employees.

What is the CDXS 52-week high?

The 52-week high for CDXS is $2.98 and the 52-week low is $0.90. The stock is currently 66.1% below its high.

Compare CDXS